Sponsored by Bristol-Myers Squibb

世界同步進行,可以到美國國家臨床試驗研究中心網站:http://clinicaltrials.gov/show/NCT00080301

目的(Purpose)

此項試驗之目的在於了解BMS-247550在於與已經核可之藥物capecitabine併用比得單用capecitabine是否可以達到較好的治療反應,治療之病患為對於anthracycline(小紅莓類藥物)及taxane(紫杉醇類藥物)都已經反應不佳之病患。關於此項治療之安全性亦將同時探討。

The purpose of this clinical research study is to learn if BMS-247550 added to the approved therapy of capecitabine is better than capecitabine alone in shrinking or slowing the growth of the cancer in women with metastatic breast cancer who are resistant to taxane and received anthracycline chemotherapy. The safety of this treatment will also be studied.

 

Condition

Treatment or Intervention

Phase

轉移性乳癌患者

Metastatic breast cancer

 藥物代表名稱: BMS-247550

第三期人體試驗

Phase III

MedlinePlus related topics:  Breast Cancer
Genetics Home Reference related topics:  breast cancer

Study Type: Interventional
Study Design: Treatment

Official Title: A Phase III Study of Novel Epothilone plus Capecitabine versus Capecitabine Alone in Patients with Advanced Breast Cancer Previously Treated with Anthracycline and who are Tazane Resistant

Eligibility

可進入試驗之條件:18歲以上之女性轉移性乳癌患者。

Ages Eligible for Study:  18 Years and above,  Genders Eligible for Study:  Female

執行定義

Criteria